Robert Gay

Robert Gay is a Director with over twenty-five years of experience in drug, medical device, and business development. Currently, they are researching and evaluating novel therapies for hearing loss and other indications. Robert has a strong track record in obtaining global regulatory approvals for high-risk Class III and Active Implantable Medical Devices, and they have extensive expertise in the development and production of monoclonal antibodies and recombinant proteins. Their professional journey includes leadership roles at major companies such as Cochlear and Cephalon, where they managed complex projects and regulatory strategies. Robert earned a PhD in Molecular Toxicology from University College London and holds a BSc (Hons) in Molecular Biology from The University of Manchester.